Reactome | CASR binds CASR agonists

CASR binds CASR agonists

Stable Identifier

R-HSA-9703895

Type

Reaction [binding]

Species

Homo sapiens

Compartment

extracellular region, plasma membrane

ReviewStatus

5/5

Locations in the PathwayBrowser

Expand all

General

SBML | | PDF

SVG | | PPTX | SBGN

Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

Patients with chronic kidney disease often develop secondary hyperparathyroidism (SHPT), marked by high levels of circulating parathyroid hormone (PTH) and increased risk of morbidity and mortality. A novel peptide, etelcalcetide (AMG 416), acts as an agonist of the calcium-sensing receptor (CaSR). Etelcalcetide activates the human CaSR in vitro and reduces serum parathyroid hormone and FGF23 levels in healthy male subjects (Walter et al. 2013, Martin et al. 2014). As a long-acting CaSR agonist, etelcalcetide is an innovative new therapy for the treatment of hemodialysis patients with secondary hyperparathyroidism (Patel & Bridgeman 2018) instead of the conventional calcimimetic cinacalcet. Evocalcet is another calcium-sensing receptor (CASR) agonist recently approved in Japan for the treatment of secondary hyperparathyroidism in dialysis patients (Kawata et al. 2018, Akizawa et al. 2019). Cinacalcet, an oral calcimimetic, binds to the transmembrane domain of the CaSR and decreases PTH, calcium, and phosphorus levels. It is used to treat hyperparathyroidism due to parathyroid tumours or renal failure (Block et al. 2010, Chertow et al. 2012, Raggi et al. 2011, Akizawa et al. 2016).

Literature References

PubMed ID	Title	Year
21148030	The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis Dehmel, B, Nossuli, K, Downey, G, Moustafa, M, Floege, J, ADVANCE Study Group, -, Naso, A, Torres, PU, Chertow, GM, Csiky, B, Raggi, P, Goodman, WG, Lopez, N	2011
23121374	Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis Trotman, ML, Mix, TC, Parfrey, PS, Kubo, Y, Floege, J, Moe, SM, Chertow, GM, Mahaffey, KW, Block, GA, Herzog, CA, Correa-Rotter, R, EVOLVE Trial Investigators, -, Drüeke, TB, Goodman, WG, Wheeler, DC, London, GM	2012
29614098	A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro Fukagawa, M, Akizawa, T, Miyazaki, H, Tokunaga, S, Haruyama, W, Hisada, Y, Masuda, N, Wada, M, Yanagida, T, Shoukei, Y, Murai, M, Kawata, T	2018
23674604	Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients Baruch, A, Janes, J, Johnson, RM, Hunter, T, Bell, G, Karim, F, Dong, J, Walter, S, Tomlinson, JE, Maclean, D, Yin, Q, Alexander, ST, Mendel, DB	2013
20555319	Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients Block, GA, St Peter, WL, Nieman, K, Liu, J, Zaun, D, Persky, M, Smits, G, Brillhart, S	2010
27071541	PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism Fukagawa, M, Yamaguchi, T, Hasegawa, T, Akizawa, T, Alan Brookhart, M, Kurokawa, K, Fukuma, S, Onishi, Y, Ellis, AR, Fukuhara, S, Mizobuchi, M, Kurita, N	2016
24235081	Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects Peacock, M, Hodsman, P, Bell, G, Vick, A, Huang, S, Martin, KJ, Pickthorn, K	2014